Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

C-terminal peptides of tissue factor pathway inhibitor are novel host defense molecules.

Papareddy P, Kalle M, Kasetty G, Mörgelin M, Rydengård V, Albiger B, Lundqvist K, Malmsten M, Schmidtchen A.

J Biol Chem. 2010 Sep 3;285(36):28387-98. doi: 10.1074/jbc.M110.127019. Epub 2010 Jun 30.

2.

Antimicrobial activity of human prion protein is mediated by its N-terminal region.

Pasupuleti M, Roupe M, Rydengård V, Surewicz K, Surewicz WK, Chalupka A, Malmsten M, Sörensen OE, Schmidtchen A.

PLoS One. 2009 Oct 7;4(10):e7358. doi: 10.1371/journal.pone.0007358.

3.

Tissue factor pathway inhibitor 2 is found in skin and its C-terminal region encodes for antibacterial activity.

Papareddy P, Kalle M, Sørensen OE, Lundqvist K, Mörgelin M, Malmsten M, Schmidtchen A.

PLoS One. 2012;7(12):e52772. doi: 10.1371/journal.pone.0052772. Epub 2012 Dec 26.

4.

Fragmented tissue factor pathway inhibitor (TFPI) and TFPI C-terminal peptides eliminate serum-resistant Escherichia coli from blood cultures.

Schirm S, Liu X, Jennings LL, Jedrzejewski P, Dai Y, Hardy S.

J Infect Dis. 2009 Jun 15;199(12):1807-15. doi: 10.1086/599097.

PMID:
19456231
5.

Antimicrobial peptides derived from growth factors.

Malmsten M, Davoudi M, Walse B, Rydengård V, Pasupuleti M, Mörgelin M, Schmidtchen A.

Growth Factors. 2007 Feb;25(1):60-70.

PMID:
17454151
6.

Thymic stromal lymphopoietin exerts antimicrobial activities.

Sonesson A, Kasetty G, Olin AI, Malmsten M, Mörgelin M, Sørensen OE, Schmidtchen A.

Exp Dermatol. 2011 Dec;20(12):1004-10. doi: 10.1111/j.1600-0625.2011.01391.x.

PMID:
22092577
7.

Structure-activity studies and therapeutic potential of host defense peptides of human thrombin.

Kasetty G, Papareddy P, Kalle M, Rydengård V, Mörgelin M, Albiger B, Malmsten M, Schmidtchen A.

Antimicrob Agents Chemother. 2011 Jun;55(6):2880-90. doi: 10.1128/AAC.01515-10. Epub 2011 Mar 14.

8.

Structure and functions of endotoxin-binding peptides derived from CAP18.

Hirata M, Zhong J, Wright SC, Larrick JW.

Prog Clin Biol Res. 1995;392:317-26.

PMID:
8524937
9.

Vertebrate TFPI-2 C-terminal peptides exert therapeutic applications against Gram-negative infections.

Kasetty G, Smeds E, Holmberg E, Wrange L, Adikesavan S, Papareddy P.

BMC Microbiol. 2016 Jun 27;16(1):129. doi: 10.1186/s12866-016-0750-3.

10.

CCL28 has dual roles in mucosal immunity as a chemokine with broad-spectrum antimicrobial activity.

Hieshima K, Ohtani H, Shibano M, Izawa D, Nakayama T, Kawasaki Y, Shiba F, Shiota M, Katou F, Saito T, Yoshie O.

J Immunol. 2003 Feb 1;170(3):1452-61.

11.

Leptoglycin: a new Glycine/Leucine-rich antimicrobial peptide isolated from the skin secretion of the South American frog Leptodactylus pentadactylus (Leptodactylidae).

Sousa JC, Berto RF, Gois EA, Fontenele-Cardi NC, Honório JE Jr, Konno K, Richardson M, Rocha MF, Camargo AA, Pimenta DC, Cardi BA, Carvalho KM.

Toxicon. 2009 Jul;54(1):23-32. doi: 10.1016/j.toxicon.2009.03.011. Epub 2009 Mar 17.

PMID:
19298834
12.

Rational design of antimicrobial C3a analogues with enhanced effects against Staphylococci using an integrated structure and function-based approach.

Pasupuleti M, Walse B, Svensson B, Malmsten M, Schmidtchen A.

Biochemistry. 2008 Sep 2;47(35):9057-70. doi: 10.1021/bi800991e. Epub 2008 Aug 9.

PMID:
18690701
13.

Synthesis, characterization, antimicrobial activity and LPS-interaction properties of SB041, a novel dendrimeric peptide with antimicrobial properties.

Bruschi M, Pirri G, Giuliani A, Nicoletto SF, Baster I, Scorciapino MA, Casu M, Rinaldi AC.

Peptides. 2010 Aug;31(8):1459-67. doi: 10.1016/j.peptides.2010.04.022. Epub 2010 May 10.

PMID:
20438783
14.

Antimicrobial activity of peptides derived from human ß-amyloid precursor protein.

Papareddy P, Mörgelin M, Walse B, Schmidtchen A, Malmsten M.

J Pept Sci. 2012 Mar;18(3):183-91. doi: 10.1002/psc.1439. Epub 2012 Jan 16.

PMID:
22249992
15.

Influence of N-terminus modifications on the biological activity, membrane interaction, and secondary structure of the antimicrobial peptide hylin-a1.

Crusca E Jr, Rezende AA, Marchetto R, Mendes-Giannini MJ, Fontes W, Castro MS, Cilli EM.

Biopolymers. 2011;96(1):41-8. doi: 10.1002/bip.21454.

PMID:
20560142
16.

Human lysozyme possesses novel antimicrobial peptides within its N-terminal domain that target bacterial respiration.

Ibrahim HR, Imazato K, Ono H.

J Agric Food Chem. 2011 Sep 28;59(18):10336-45. doi: 10.1021/jf2020396. Epub 2011 Sep 2.

PMID:
21851100
17.

Structural requirements of human tissue factor pathway inhibitor (TFPI) and heparin for TFPI-heparin interaction.

Ye Z, Takano R, Hayashi K, Ta TV, Kato H, Kamikubo Y, Nakahara Y, Kumeda K, Hara S.

Thromb Res. 1998 Mar 15;89(6):263-70.

PMID:
9669748
18.

Bacterial killing by heparin-binding peptides from PRELP and thrombospondin.

Malmsten M, Davoudi M, Schmidtchen A.

Matrix Biol. 2006 Jul;25(5):294-300. Epub 2006 Apr 25.

PMID:
16730966
19.

Preservation of antimicrobial properties of complement peptide C3a, from invertebrates to humans.

Pasupuleti M, Walse B, Nordahl EA, Mörgelin M, Malmsten M, Schmidtchen A.

J Biol Chem. 2007 Jan 26;282(4):2520-8. Epub 2006 Nov 27.

20.

Tissue factor pathway inhibitor: the carboxy-terminus is required for optimal inhibition of factor Xa.

Wesselschmidt R, Likert K, Girard T, Wun TC, Broze GJ Jr.

Blood. 1992 Apr 15;79(8):2004-10.

Supplemental Content

Support Center